Epsilon Healthcare Limited · ASX:EPN
Epsilon Healthcare — Investor Presentation (November 2020)
23 slides from Epsilon Healthcare's investor presentation, Nov 2, 2020
Slide 1: Diversified Healthcare and Pharmaceuticals
THC GLOBAL GROUP LIMITED (ASX:THC) TO BE RENAMED EPSILON HEALTHCARE LIMITED Diversified Healthcare and Pharmaceuticals A healthcare company with diversified investments in healthcare, pharmaceuticals, and medicinal cannabis actively operating in Australia and Canada
Slide 2: Disclaimer
The material in this presentation (Material) is not and does not Such statements relate to future events and expectations and, as such, Disclaimer constitute an offer, invitation or recommendation to subscribe for, or purchase any security in THC Global Group Limited (THC) (ACN 614 508 039) nor does
Slide 3: Healthcare and High Value Pharmaceuticals
Healthcare and High Value Pharmaceuticals Pharma Manufacturing Facility Australian Cultivation Facility New Pharma E-Commerce Platform High volume EU and TGA GMP bio-floral extraction and Licenced and permitted hydroponic cannabis Medimar platform to connect patients, prescribers, and pharmaceutical
Slide 4: Global Cannabis Business
Global Cannabis Business GMP Pharma Manufacturing Medimar Platform Licenced and permitted Australian Unique e-commerce platform TGA and EU GMP bio-floral extraction connecting patients, pharmacies, and facility now operational prescribers, streamlining distribution Cannabis Medicines Cultivation Sol
Slide 5: Strategic & Financial Review
1 Strategic & Financial Review
Slide 6: Strategic Changes
Strategic Changes Healthcare Focussed Launching the Medimar Platform Rebranding the parent company to Epsilon Offering a unique end to end e-commerce Healthcare as part of a broader shift into platform for cannabis in Australia, utilising healthcare and pharmaceuticals Southport Facility as a distri
Slide 7: Capital & Financial Overview
Capital & Financial Overview RECENT FINANCIALS Reduced Run Rate Reviewing Non-Core Activities Cash Identified and implemented over $3m in Reviewing future of Australian cannabis $7.26 million 30 September annualised run rate savings, expected to be cultivation, and exploring divestment fully realise
Slide 8: Corporate Rebranding
Corporate Rebranding Healthcare and Pharmaceuticals Change of name and branding supports a move towards patient led healthcare and high value pharmaceutical production Broader than Cannabis Moving away from reference to “THC” given perception that “THC” is related to the recreational cannabis market
Slide 9: Australian Medicinal Cannabis and Pharmaceuticals
2 Australian Medicinal Cannabis and Pharmaceuticals
Slide 10: Pharma Manufacturing
Pharma Scalable Production Potential for production ramp up to support over 1 million Manufacturing patients per annum at existing facility enables discussions with global partners for high volume medicines manufacture PIVOTING TOWARDS TOLL MANUFACTURING Broad Production Capability Moving away from
Slide 11: Australian Cultivation
Australian Cultivation Outlook Australian Assets • Reviewing value in continuing to cultivate own • Fully licenced and permitted hydroponic cannabis within Australia greenhouse for cannabis cultivation in Bundaberg, • Temporary suspension of activities at Bundaberg Queensland Facility during review
Slide 12: Own Brand Medicines
Own Brand Medicines CanndeoCare Project Uno • Production of CanndeoCare branded medicines to • ‘Uno’ to be launched as the Company’s new brand taper down over early 2021 in support of a primarily for niche or unique cannabis medicines for toll manufacturing based approach for the Australian and expo
Slide 13: Medimar Platform
Medimar A proprietary end to end e-commerce platform for the ordering and dispensing of medicinal cannabis, reducing admin burden on prescribers and pharmacies, enabled by the Company’s licenced distribution facility. Platform Prescribers Pharmacies Patients Distribution Reduces admin workload for I
Slide 14: Medimar Platform
Medimar Platform REGISTRATIONS COMMENCE FOR PRESCRIBERS, PHARMACIES, AND SUPPLIERS BY MID-NOV WITH FULL LAUNCH EXPECTED IN JANUARY 2021 medimar.com.au INDICATIVE DESIGN
Slide 15: Tetra Health
Tetra Health TELEHEALTH CLINIC SPECIALISING IN MEDICINAL CANNABIS For patients, Tetra Health is an easy way to access medicinal cannabis through a network of telehealth physicians and with ongoing support from a team of nurses based in Australia. For suppliers, Tetra Health is a high volume product
Slide 16: Australian Cannabis Value Chain
Australian Cannabis Value Chain Control of entire value chain from plant material, through to end distribution to patients or export markets with revenue touchpoints at each step Contract Cultivation Medimar Platform Southport GMP Partner Supplied Manufacturing Tetra Health Plant Material R&D Formul
Slide 17: Hydroponics and Canadian Cannabis
3 Hydroponics and Canadian Cannabis
Slide 18: Hydroponics Equipment
Hydroponics Equipment Continued Revenue Growth Expanding Distribution Diversified Product Range Servicing a Large Market Revenue for the year to the end of In addition to export opportunities, CMP range includes over 1,000 The home grower and small Sept 2020 for CMP has exceeded the Company is addit
Slide 19: Cannabis Services and Retailing
Cannabis Services and Retailing Turnkey Solutions Additional Revenue Advisory Services Providing turnkey cultivation Advisory and solutions provider, Advisory services offered by solutions under the Canndeo Canndeo Fulfilment, achieved Q3 Canndeo Fulfilment are targeted brand combining equipment, re
Slide 20: Corporate Structure
4 Corporate Structure
Slide 21: Global Management Team
Steven Xu Alan Beasley Jarrod White Sonny Didugu Non-Exec Chairman Non-Exec Deputy Chairman Interim Group Chief Executive Group Chief Operating Officer Officer & Chief Financial Officer & Joint Company Secretary Global Management Team Laura Harvey Angela Macquire Diandra Phipps Philip Leighfield Chi
Slide 22: Capital & Financial Information
Capital & Financial Information KEY INFORMATION RECENT FINANCIAS ASX code Cash $7.26 million ASX:THC 30 September Listing Date May 2017 Q3 Receipts from Customers $2.12 million Appendix 4C Pharmaceuticals, Biotechnology Q3 Net Cash from Operating Activities GICS Classification -$2.52 million & Life
Slide 23: THC Global Group
THC Global Group Corporate Office Suite 4102 Level 41 Australian Square (ASX:THC) 264-278 George Street Sydney NSW 2000 Australia TO BE RENAMED Epsilon Healthcare Limited Email us at (Subject to approval) corporate@thc.global Visit us at thc.global
Epsilon Healthcare — Investor Presentation (November 2020) on 6ix